Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial

Harvey D. White, Neal S. Kleiman, Kenneth W. Mahaffey, Yuliya Lokhnygina, Karen S. Pieper, Karen Chiswell, Marc Cohen, Robert A. Harrington, Derek P. Chew, John L. Petersen, Lisa G. Berdan, Philip E G Aylward, Christopher C. Nessel, James J. Ferguson, Robert M. Califf

Research output: Contribution to journal › Article › peer-review

84 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial'. Together they form a unique fingerprint.

Medicine & Life Sciences